Table 3. Association between CTNNB1 rs1880481 and rs3864004 and the efficacy of RT at the lymph node in NPC patients.

Time	SNP	Genotype distributiona		Model	Unadjusted		Adjustedb,c
		Non-CR (MAF)	CR (MAF)		OR(95%CI)	P	OR(95%CI)	P
After RT	rs1880481	4/7/11	6/51/76	allelic	1.67 (0.84–3.30)	0.141	—	—
		(0.34)	(0.24)	addictive	1.67 (0.84–3.33)	0.147	1.71 (0.81–3.60)	0.156
				dominant	1.33 (0.54–3.29)	0.533	1.54 (0.57–4.22)	0.397
				recessive	4.70 (1.21–18.29)	0.025	3.79 (0.84–17.17)	0.084
3 months	rs1880481	3/3/6	6/36/60	allelic	1.95 (0.80–4.74)	0.135	—	—
after RT		(0.38)	(0.24)	addictive	1.85 (0.78–4.36)	0.160	1.82 (0.76–4.31)	0.177
				dominant	1.43 (0.43–4.74)	0.560	1.44 (0.43–4.90)	0.555
				recessive	5.33 (1.14–25.01)	0.034	5.05 (1.02–25.03)	0.048
	rs3864004	2/4/6	3/40/58	allelic	1.70 (0.68–4.21)	0.251	—	—
		(0.33)	(0.23)	addictive	1.78 (0.68–4.68)	0.240	1. 73 (0.62–4.87)	0.299
				dominant	1.35 (0.41–4.47)	0.625	1.19 (0.34–4.18)	0.788
				recessive	6.53 (0.97–43.85)	0.053	10.50 (1.03–106.60)	0.047

^aIn the order of homozygote /heterozygote/ wild type.

^bAdjusted for M stage for the association between SNPs and the efficacy of RT at the lymph node.

^cAdjusted for age for the association between SNPs and the efficacy of RT at the lymph node 3 months after treatment.

Abbreviations: RT, radiotherapy; CR, complete remission; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.

P value < 0.05 is shown in bold.